Discussão:Didier Raoult
Adicionar tópico| Esta é a página de discussão de Didier Raoult, destinada ao debate sobre melhorias e tarefas relacionadas ao artigo. Não é um fórum para discussão sem relação com o artigo. | |||
|---|---|---|---|
|
|||
Este artigo tem um claro viés político. Nao oferece informações atualizadas acerca da ineficiência comprovada da Cloroquina frente ao SARS Cov-2 A versão em inglês está devidamente atualizada.
https://en.m.wikipedia.org/wiki/Chloroquine_and_hydroxychloroquine_during_the_COVID-19_pandemic
Drugs used for treatment of infectious diseases may also be considered for use for post-exposure prophylaxis. On 22 May, The Lancet published a response to criticism of the Indian government's decision to allow chemoprophylaxis with hydroxychloroquine for some high risk persons who may have had exposure to COVID. Researchers supporting prophylactic administration of hydroxychloquine note that results from human trials have suggested that hydroxychloroquine may decrease the duration of both viral shedding and symptoms if the drug is administered early.[53]
On 3 June, results were published from a randomized, double-blind, placebo-controlled trial of 821 participants which found that hydroxychloroquine did not prevent symptomatic COVID-19 illness when used for post-exposure prophylaxis.[54][55][56]
British researchers are studying whether the drug is effective when used for prevention. 10,000 National Health Service (NHS) workers, along with 30,000 additional volunteers from Asia, South America, Africa, and other parts of Europe are participating in the global study. Results are expected by in 2021.[57][58]